HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.

AbstractBACKGROUND:
Current research diagnostic criteria for Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD include biomarkers to supplement clinical testing. Recently, we demonstrated that dual time-point [18F]FBB PET is able to deliver both blood flow and amyloid-β (Aβ) load surrogates.
OBJECTIVE:
The aim of this study was to investigate whether these surrogates can be utilized as AD biomarkers.
METHODS:
112 subjects (41 with MCI, 50 with probable/possible AD, 21 with other dementias) underwent dual time-point [18F]FBB PET. Data were visually and relative quantitatively (Herholz scores for the early and composite SUVRs for the late PET data) analyzed.
RESULTS:
In the early images AD-typical patterns were present in 42% /27% /33% of probable/possible AD/MCI/other dementia cases. In late [18F]FBB PET, 42% /29% /38% of probable/possible AD/ MCI/other dementia cases were Aβ-positive. 17% of the MCIs were categorized as "MCI due to AD-high likelihood", 44% of the probable ADs as "probable AD with high evidence of AD pathophysiological process" and 28% of the possible ADs as "possible AD with evidence of AD pathophysiological process". 27% of all subjects showed a positive diagnostic and progression biomarker. Herholz scores were lower (0.85±0.05 versus 0.88±0.04, p = 0.015) for probable/possible AD versus MCI. Composite late phase SUVRs were significantly higher (1.65±0.23 versus 1.15±0.17, p < 0.005) in Aβ-positive versus Aβ-negative patients. Herholz and MMSE scores were positively correlated (R = 0.30 p = 0.006).
CONCLUSION:
Dual time-point [18F]FBB PET provides dual biomarker information which enables to categorize MCI and AD dementia patients according to established diagnostic criteria. Thus, dual time-point [18F]FBB PET has great potential to supplement diagnostic dementia workups.
AuthorsLisa Florek, Solveig Tiepolt, Matthias L Schroeter, Jörg Berrouschot, Dorothee Saur, Swen Hesse, Thies Jochimsen, Julia Luthardt, Bernhard Sattler, Marianne Patt, Karl-Titus Hoffmann, Arno Villringer, Joseph Classen, Hermann-Josef Gertz, Osama Sabri, Henryk Barthel
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 66 Issue 3 Pg. 1105-1116 ( 2018) ISSN: 1875-8908 [Electronic] Netherlands
PMID30400095 (Publication Type: Journal Article, Observational Study)
Chemical References
  • Aniline Compounds
  • Biomarkers
  • Fluorine Radioisotopes
  • Stilbenes
  • 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
Topics
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease (diagnostic imaging)
  • Aniline Compounds
  • Biomarkers
  • Brain (diagnostic imaging)
  • Cognitive Dysfunction (diagnostic imaging)
  • Diagnosis, Differential
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Neuroimaging (methods)
  • Positron-Emission Tomography (methods)
  • Retrospective Studies
  • Stilbenes

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: